Applications of dynamic gratings in neuro-ophthalmic disorders - Report - MDSpire

Utilization of Dynamic Gratings in the Assessment of Neuro-Ophthalmic Conditions

  • By

  • Xinzuo Zhou

  • Yuexin Wang

  • July 20, 2026

Share

Clinical Report: Utilization of Dynamic Gratings in Neuro-Ophthalmic Assessment

Overview

Dynamic gratings offer a novel approach for assessing visual function in neuro-ophthalmic conditions, engaging specific visual pathways.

Background

Traditional visual assessments often fail to detect early and subtle visual impairments, particularly in neuro-ophthalmic disorders. Dynamic gratings can provide insights into the functioning of distinct visual pathways.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

  • Dynamic gratings can preferentially engage magnocellular and parvocellular pathways.
  • Five primary motion patterns of dynamic gratings include phase-alternating oscillation, drift, translation, appearance-disappearance, and rapid serial visual presentation.
  • Parameter modulation of dynamic gratings allows for the collection of psychophysical and neurophysiological responses.
  • Dynamic gratings have applications in diagnosing and evaluating conditions such as glaucoma, amblyopia, and multiple sclerosis.

Clinical Implications

The integration of dynamic gratings into clinical practice could enhance the detection of visual dysfunctions in neuro-ophthalmic conditions.

Conclusion

Dynamic gratings represent a tool for advancing the assessment of visual function in neuro-ophthalmic disorders.

Related Resources & Content

  1. Glaucoma Physician, 2019 -- Best Approaches to Early Glaucoma Diagnosis
  2. Ophthalmology Management, 2019 -- Uncovering early glaucoma
  3. Ophthalmology Management, 2024 -- DIFFERENTIATING MYOPIA AND GLAUCOMA
  4. Glaucoma Physician, 2021 -- Artificial Intelligence as a Tool for Diagnosing and Monitoring Glaucoma
  5. ISCEV standard for clinical visual evoked potentials (2025 update) - PMC
  6. Ocular Imaging and Electrophysiology - PubMed
  7. Study Details | NCT02521311 | Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER) | ClinicalTrials.gov
  8. Articles in Press: Ophthalmology
  9. ISCEV standard for clinical visual evoked potentials (2025 update) - PMC
  10. Ocular Imaging and Electrophysiology - PubMed
  11. Study Details | NCT02521311 | Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER) | ClinicalTrials.gov
  12. Articles in Press: Ophthalmology

Original Source(s)

Related Content